Study on antibacterial activity of cefoperazone sodium and tazobactam sodium in vivo / 中国药理学通报

ABSTRACT

AIM and METHOD: To investigate the antibacterial activity (ED50value) of cefoperazone sodium and tazobactam sodium (4:0.5) in vivo using minor modified Karbers method, which will offer some important evidences for clinical trial and therapy. RESULTS: The ED50 value of cefoperazone sodium and tazobactam sodium (4:0.5) and Cefoperazone sodium and sulbactam sodium (1:1) in vivo protested against zymogenic staphylococcus aureus and Escherichia coli in mice infected by these bacteria were 92.0 mg·kg-1 and 3.4 mg·kg-1, 164.0 mg·kg-1 and 6.9 mg·kg-1, respectively, and 256.5 mg·kg1 and 38.9 mg·kg-1 in single composed compound of cefoperazone sodium, cefoperazone sodium and tazobactam sodium (4:0.5) in vivo had more potent antibacterial activity compared with cefoperazone sodium and sulbactam sodium (1:1) and single composed compound of cefoperazone sodium. The ED50 value of cefoperazone sodium and tazobactam sodium (4:0.5) protested against pseudomonas aeruginosa in mice infected was lower than that of Cefoperazone sodium and sulbactam sodium and single composed compound of cefoperazone sodium. CONCLUSION: Cefoperazone sodium and tazobactam sodium made in China has an markedly therapeutic effect on antibacterial activity protected against zymogenic staphylococcus aureus and Escherichia coli and pseudomonas aeruginosa in mice infected by these bacteria.